IC
CCCC icon

Ikarian Capital’s C4 Therapeutics CCCC Stock Holding History

Ikarian Capital’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-17,600
Closed -$666K – 225
2021
Q2 		$666K Sell
17,600
-93,900
-84% -$3.36M 0.05% 175
2021
Q1 		$4.12M Sell
111,500
-40,000
-26% -$1.59M 0.14% 135
2020
Q4 		$5.02M Buy
+151,500
New +$4.39M 0.22% 95

Other funds holding CCCC

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Ikarian Capital's CCCC Position: Q3 2021 in Review

Ikarian Capital sold out of C4 Therapeutics (CCCC) in Q3 2021, closing a stake of 17,600 shares — an estimated $666K sold.

Ikarian Capital first reported a position in CCCC in Q4 2020 and held it in 3 quarters. The position peaked at $5.02M in Q4 2020. 113 funds tracked by Wall St. Rank hold CCCC as of Q3 2021.

  • Ikarian Capital reported no remaining C4 Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Ikarian Capital sold 17,600 C4 Therapeutics shares in Q3 2021, an estimated $666K.
  • Ikarian Capital first reported a position in C4 Therapeutics in Q4 2020 and held it in 3 quarters.
  • Ikarian Capital's C4 Therapeutics position peaked at $5.02M in Q4 2020.
  • 113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2021.

Based on Ikarian Capital's 13F filing for Q3 2021, filed 15 Nov 2021.